Imaging Brain Iron and Diffusion Patterns. A Follow-up Study of Parkinson's Disease in the Initial Stages.

Academic Radiology

Volumn 21, Issue 1, 2014, Pages 64-71

  Rossi, Maija Elina ^a   Ruottinen, Hanna ^a   Saunamäki, Tiia ^a   Elovaara, Irina ^a,b   Dastidar, Prasun ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Brain iron; Diffusion tensor imaging; Magnetic resonance imaging; Parkinson's disease

Indexed keywords

IRON;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONA RADIATA (BRAIN); CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DISEASE DURATION; EXTERNAL CAPSULE; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; GLOBUS PALLIDUS; HUMAN; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL LOBE; PARIETAL LOBE; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SUSCEPTIBILITY WEIGHTED IMAGING; THALAMUS; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

BRAIN IRON; DIFFUSION TENSOR IMAGING; MAGNETIC RESONANCE IMAGING; PARKINSON'S DISEASE;

ADULT; AGED; ANISOTROPY; BIOLOGICAL MARKERS; BRAIN; CAUDATE NUCLEUS; DIFFUSION MAGNETIC RESONANCE IMAGING; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GLOBUS PALLIDUS; HUMANS; IRON; MALE; MIDDLE AGED; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THALAMUS; TISSUE DISTRIBUTION;

EID: 84890178799     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2013.09.018     Document Type: Article

References (45)

1. Davie C.A. A review of Parkinson's disease. Br Med Bull 2008, 86:109-127.
2. Hart R.G., Pearce L.A., Ravina B.M., et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009, 24:647-654.
3. Massano J., Garrett C. Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol 2012, 3:66.
4. Olanow C.W., Rascol O., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278. ADAGIO Study Investigators.
5. Stoessl A.J., Martin W.W., McKeown M.J., et al. Advances in imaging in Parkinson's disease. Lancet Neurol 2011, 10:987-1001.
6. Mascalchi M., Vella A., Ceravolo R. Movement disorders: role of imaging in diagnosis. J Magn Reson Imaging 2012, 35:239-256.
7. Martin W.R. Quantitative estimation of regional brain iron with magnetic resonance imaging. Parkinsonism Relat Disord 2009, 15:215-218.
8. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
9. Dexter D.T., Carayon A., Javoy-Agid F., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
10. Bartzokis G., Cummings J.L., Markham C.H., et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 1999, 17:213-222.
11. Du G., Lewis M.M., Styner M., et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011, 26:1627-1632.
12. Götz M.E., Double K., Gerlach M., et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004, 1012:193-208.
13. Antonini A., Leenders K.L., Meier D., et al. T2 relaxation time in patients with Parkinson's disease. Neurology 1993, 43:697-700.
14. Graham J.M., Paley M.N., Grünewald R.A., et al. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000, 123:2423-2431.
15. Kosta P., Argyropoulou M.I., Markoula S., et al. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006, 253:26-32.
16. Xu X., Wang Q., Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an invivo MRI study. Neuroimage 2008, 40:35-42.
17. Smith S.M., Jenkinson M., Woolrich M.W., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004, 23:208-219.
18. Smith S.M., Jenkinson M., Johansen-Berg H., et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006, 31:1487-1505.
19. Smith S.M. Fast robust automated brain extraction. Hum Brain Mapp 2002, 17:143-155.
20. Pfefferbaum A., Adalsteinsson E., Rohlfing T., et al. Diffusion tensor imaging of deep gray matter brain structures: effects of age and iron concentration. Neurobiol Aging 2010, 31:482-493.
21. Vaillancourt D.E., Spraker M.B., Prodoehl J., et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
22. Karagulle Kendi A.T., Lehericy S., Luciana M., et al. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008, 29:501-505.
23. Litvan I., Goldman J.G., Tröster A.I., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356.
24. Lichy M.P., Wietek B.M., Mugler J.P., et al. Magnetic resonance imaging of the body trunk using a single-slab, 3-dimensional, T2-weighted turbo-spin-echo sequence with high sampling efficiency (SPACE) for high spatial resolution imaging: initial clinical experiences. Invest Radiol 2005, 40:754-760.
25. Haacke E.M., Mittal S., Wu Z., et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009, 30:19-30.
26. Mittal S., Wu Z., Neelavalli J., et al. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009, 30:232-252.
27. Welsch G.H., Trattnig S., Hughes T., et al. T2 and T2* mapping in patients after matrix-associated autologous chondrocyte transplantation: initial results on clinical use with 3.0-Tesla MRI. Eur Radiol 2010, 20:1515-1523.
28. Welsch G.H., Mamisch T.C., Hughes T., et al. Invivo biochemical 7.0 Tesla magnetic resonance: preliminary results of dGEMRIC, zonal T2, and T2* mapping of articular cartilage. Invest Radiol 2008, 43:619-626.
29. Rossi M., Ruottinen H., Elovaara I., et al. Brain iron deposition and sequence characteristics in parkinsonism: comparison of SWI, T2* Maps, T2-weighted- and FLAIR-SPACE. Invest Radiol 2010, 45:795-802.
30. Rossi M., Ruottinen H., Soimakallio S., et al. Clinical MRI for iron detection in Parkinson's disease. Clin Imaging 2013, 37:631-636.
31. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958, 3:41-51.
32. Gröger A., Berg D. Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm 2012, 119:1523-1528.
33. Ryvlin P., Broussolle E., Piollet H., et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 1995, 52:583-588.
34. Wallis L.I., Paley M.N., Graham J.M., et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008, 28:1061-1067.
35. Zhang W., Sun S.G., Jiang Y.H., et al. Determination of brain iron content in patients with Parkinson's disease using magnetic susceptibility imaging. Neurosci Bull 2009, 25:353-360.
36. Zhang J., Zhang Y., Wang J., et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an invivo MR study. Brain Res 2010, 1330:124-130.
37. Burzynska A.Z., Preuschhof C., Bäckman L., et al. Age-related differences in white matter microstructure: region-specific patterns of diffusivity. Neuroimage 2010, 49:2104-2112.
38. Haller S., Badoud S., Nguyen D., et al. Individual detection of patients with Parkinson disease using support vector machine analysis of diffusion tensor imaging data: initial results. AJNR Am J Neuroradiol 2012, 33:2123-2128.
39. Tessa C., Giannelli M., Della Nave R., et al. A whole-brain analysis in de novo Parkinson disease. AJNR Am J Neuroradiol 2008, 29:674-680.
40. Haacke E.M., Cheng N.Y., House M.J., et al. Imaging iron stores in the brainusing magnetic resonance imaging. Magn Reson Imaging 2005, 23:1-25.
41. Deistung A., Schweser F., Wiestler B., et al. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One 2013, 8:e57924.
42. Li M., Hu J., Miao Y., et al. Invivo measurement of oxygenation changes after stroke using susceptibility weighted imaging filtered phase data. PLoS One 2013, 8:e63013.
43. Haller S., Badoud S., Nguyen D., et al. Differentiation between Parkinson disease and other forms of Parkinsonism using support vector machine analysis of susceptibility-weighted imaging (SWI): initial results. Eur Radiol 2013, 23:12-19.
44. Walsh A.J., Lebel R.M., Eissa A., et al. Multiple sclerosis: validation of MR imaging for quantification and detection of iron. Radiology 2013, 267:531-542.
45. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.